Isocyclosporin A for topical treatment of ocular diseases

Patent metadata

Field	Value
Publication number	US-12558399-B2
Application number	US-202218722415-A
Country	US
Kind code	B2
Filing date	Dec 22, 2022
Priority date	Dec 24, 2021
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

The present invention relates to isocyclosporin A, salts and ophthalmic compositions thereof for ophthalmic topical use in the prevention or treatment in an individual of an ophthalmic inflammatory and/or autoimmune disease, preferably selected from corneal and ocular surface inflammatory and/or autoimmune diseases and eyelid margin inflammatory diseases.

First claim

The invention claimed is:

1 . A method of treating an inflammatory and/or autoimmune ophthalmic disease in a human subject in need thereof, the method comprising the step of ophthalmically topically administering to the subject a composition comprising isocyclosporin A or an ophthalmically acceptable salt thereof.

2 . The method of claim 1 , wherein an inflammatory ophthalmic disease selected from a corneal and ocular surface inflammatory disease and an eyelid margin inflammatory disease is treated.

3 . The method of claim 2 , wherein the corneal and ocular surface inflammatory disease is selected from vernal keratoconjunctivitis (VKC), atopic keratoconjunctivitis (AKC), allergic conjunctivitis, ocular rosacea, uveitis, dry eye disease (DED), ocular cicatricial pemphigoid (OCP), ocular graft-versus-host disease (GVHD), or immune corneal ulcers.

4 . The method of claim 2 , wherein the eyelid margin inflammatory disease is selected from inflamed pterygium or chronic blepharitis.

5 . The method of claim 1 , wherein the ophthalmically acceptable salt is selected from acetate, adipate, ascorbate, benzoate, benzenesulfonate, bicarbonate, bisulfate, butyrate, camphorate, camphorsulfonate, citrate, cyclohexyl sulfamate, ethanesulfonate, fumarate, glutamate, glycolate, hemisulfate, 2-hydroxyethylsulfonate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, hydroxymaleate, lactate, malate, maleate, methanesulfonate, 2-naphthalenesulfonate, nitrate, oxalate, pamoate, persulfate, phenylacetate, phosphate, diphosphate, picrate, pivalate, propionate, quinate, salicylate, stearate, succinate, sulfamate, sulfanilate, sulfate, tartrate, p-toluenesulfonate, trifluoroacetate and undecanoate salts of isocyclosporin A.

6 . The method of claim 1 , wherein the composition is a liquid ophthalmic formulation.

7 . The method of claim 6 , wherein the liquid ophthalmic formulation is an eye drop liquid formulation.

8 . The method of claim 7 , wherein the liquid ophthalmic composition comprises an aqueous solution, a biphasic liquid formulation, a micro-emulsion, or a physiological saline solution.

9 . The method of claim 1 , wherein the composition a semi-solid ophthalmic formulation.

10 . The method of claim 9 , wherein the semi-solid ophthalmic formulation is a cream, an ointment, or a gel.

11 . The method of claim 1 , wherein the composition has a pH between 6 and 8.

12 . The method of claim 1 , further comprising administering at least one drug suitable for treatment of inflammatory and/or autoimmune ophthalmic diseases.

13 . The method of claim 12 , wherein the at least one drug comprises a corticosteroid.

14 . The method of claim 1 , further comprising administering a cyclosporin.

15 . The method of claim 5 , wherein the ophthalmically acceptable salt is a hydrochloride salt of isocyclosporin A.

16 . The method of claim 5 , wherein the ophthalmically acceptable salt is a trifluoroacetate salt of isocyclosporin A.

17 . The method of claim 1 , wherein the inflammatory and/or autoimmune ophthalmic disease is atopic keratoconjunctivitis (AKC).

18 . A method of treating atopic keratoconjunctivitis (AKC) in a human subject in need thereof, the method comprising the step of ophthalmically topically administering to the subject a composition comprising isocyclosporin A or an ophthalmically acceptable salt thereof.

19 . The method of claim 18 , wherein the ophthalmically acceptable salt is a hydrochloride salt of isocyclosporin A.

20 . The method of claim 18 , wherein the ophthalmically acceptable salt is a trifluoroacetate salt of isocyclosporin A.

Assignees

• Dompe Farm Spa

Inventors

• Macchi Ilaria

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/0048 Primary

  Eye, e.g. artificial tears · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P27/02

  Ophthalmic agents · CPC title